MipSalus is dedicated to developing new, non-systemic pharmaceutical drugs for treatment of metabolic orphan diseases
Chief Executive Officer
Chief Scientific Officer
Chief Operating Officer
Chairman of the Board
Board Member
Board Member
Board Member
MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment for the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to prevent uptake of surplus dietary phenylalanine (Phe) in the body.
The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.
